Clinical Trials for Colon Cancer

A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable metastatic colorectal cancer and ECOG performance status 0–1 are eligible; prior c-Met–targeted therapy or irinotecan or another topoisomerase inhibitor is excluded. The study tests telisotuzumab adizutecan, a c-Met–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor, with FOLFOX/bevacizumab or fluorouracil/leucovorin/panitumumab, compared with regimens without telisotuzumab adizutecan.

ClinicalTrials.gov ID: NCT06820463

A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with inoperable, measurable microsatellite-stable or mismatch repair–proficient colorectal cancer after up to three prior treatment lines are randomized to DSP107 plus atezolizumab or fruquintinib. DSP107 is an investigational SIRPα–4-1BBL fusion protein designed to block CD47–SIRPα signaling and stimulate T and NK cells.

ClinicalTrials.gov ID: NCT07235293

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic KRAS G12D-mutated colorectal adenocarcinoma and ECOG 0–1 receive investigational oral VS-7375, an inhibitor of active and inactive KRAS G12D. Previously treated patients receive it alone or with cetuximab or panitumumab; first-line patients receive it with cetuximab and mFOLFOX6.

ClinicalTrials.gov ID: NCT07659795

A Phase 2, Randomized, Open-label Study of VVD-133214 in COmbination With Pembrolizumab Compared to Pembrolizumab Monotherapy in Participants With Advanced Colorectal Adenocarcinoma (CRC) Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (DMMR)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated unresectable or metastatic MSI/dMMR colorectal adenocarcinoma are randomized to pembrolizumab alone or pembrolizumab plus one of two doses of oral VVD-133214. VVD-133214 is an investigational WRN helicase inhibitor designed to exploit MSI/dMMR tumors’ dependence on WRN-mediated DNA maintenance.

ClinicalTrials.gov ID: NCT07811193

A Single-Arm, Phase II Study Evaluating Combination Balstilimab Plus Botensilimab With AgenT-797 in Previously Treated Patients With pMMR Metastatic CRC With Liver Metastases

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated pMMR/MSS metastatic colorectal cancer and measurable liver metastases receive balstilimab (anti-PD-1), botensilimab (Fc-enhanced anti-CTLA-4), and agenT-797, an allogeneic invariant natural killer T-cell therapy that recognizes CD1d-presented glycolipid antigens. Patients must have received fluorouracil, oxaliplatin, and irinotecan, plus an EGFR inhibitor or bevacizumab when appropriate, and must not have had prior immunotherapy.

ClinicalTrials.gov ID: NCT07550088

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent IDH-mutant astrocytoma or IDH-wildtype glioblastoma after radiation-based treatment receive oral NEO212 alone; patients with selected solid tumors and brain metastases uncontrolled by surgery or radiation receive it with tumor-appropriate standard-of-care therapy. NEO212 is an investigational temozolomide–perillyl alcohol conjugate that acts as a DNA-alkylating agent.

ClinicalTrials.gov ID: NCT06047379

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of RBS2418 Plus Best Supportive Care (BSC) in Subjects with Advanced, Metastatic, and Progressive Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with progressive metastatic colorectal cancer who have exhausted, cannot tolerate, or declined standard therapies are randomized within ENPP1/cGAS biomarker groups to oral RBS2418 plus best supportive care or placebo plus best supportive care. RBS2418 inhibits ENPP1 to preserve extracellular cGAMP and promote antitumor immune activity.

ClinicalTrials.gov ID: NCT06824064

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1, measurable disease, and an injectable, biopsiable lesion may enroll in cohorts for untreated PD-L1-positive advanced head and neck squamous-cell carcinoma or advanced melanoma progressing on or after anti-PD-(L)1 therapy; the previously treated, non–MSI-high advanced colorectal cancer cohort is closed. Treatment combines intratumoral VV1, an engineered oncolytic virus designed to kill tumor cells and stimulate immunity, with intravenous cemiplimab, an anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT04291105

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic endometrial, gastric, castration-resistant prostate, ovarian, colorectal, urothelial, or biliary tract cancer receive datopotamab deruxtecan, a TROP2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor, either alone or in tumor-specific combinations. Combination partners include fluoropyrimidines, platinum chemotherapy, bevacizumab, corticosteroids, or the investigational bispecific antibodies volrustomig (PD-1/CTLA-4) and rilvegostomig (PD-1/TIGIT).

ClinicalTrials.gov ID: NCT05489211

A Phase Ib/II Basket Study of BMS-986504 in Combination With Pemetrexed for Metastatic Solid Tumors With MTAP Deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic solid tumors harboring homozygous MTAP deletion who have progressed after at least one standard systemic regimen receive oral BMS-986504 plus intravenous pemetrexed. BMS-986504 is an investigational MTA-cooperative PRMT5 inhibitor designed to exploit MTAP-deletion–associated synthetic lethality.

ClinicalTrials.gov ID: NCT07594626